ArticleLipids in health and disease2025
Long-term trajectories of apolipoprotein A1 and major adverse cardiovascular events and mortality in a community cohort.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Per- and Polyfluoroalkyl Substances Exposure and Ischemic Heart Disease: Emerging Evidence from the Literature.Antioxidants (Basel, Switzerland) · 2026Review
- Machine learning prediction of sudden cardiac death incorporating multiple lipid markers: evidence from the Taiwan Chin Shan community cohort.Lipids in health and disease · 2026Article
- From polyclonal to monoclonal: de novo sequencing of goat antibodies for a standardized ApoA-I immunoturbidimetric assay.Journal of biological engineering · 2026Article
- Atherogenic Index of Plasma and Residual Risk in Anticoagulated Patients With Atrial Fibrillation: The Prospective Murcia Atrial Fibrillation Project III Cohort.Journal of the American Heart Association · 2026Article
- Relation of the stress hyperglycaemia ratio to residual risk in anticoagulated patients with atrial fibrillation: A report from the prospective Murcia AF Project III cohort.Diabetes, obesity & metabolism · 2026Article
- Relation of the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio to residual risk in anticoagulated patients with atrial fibrillation: a report from the prospective Murcia AF Project III cohort.Cardiovascular diabetology · 2025Observational
- Early blood pressure response index and mortality risk in cardiogenic shock: evidence from two critical care cohorts.BMC cardiovascular disorders · 2025Article
- Toward Better Risk Stratification After Iliofemoral Endovascular Therapy in Lower Extremity Artery Disease.JACC. Asia · 2025Article
- Remnant-to-LDL cholesterol discordance as a predictor of thromboembolic events in anticoagulated patients with atrial fibrillation: a report from the prospective Murcia AF project III (MAFP-III) cohort study.Cardiovascular diabetology · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundApolipoprotein A1 (ApoA1) is a major component of high-density lipoprotein cholesterol and plays a critical role in reverse cholesterol transport. Dynamic changes in ApoA1 levels may be associated with major adverse cardiovascular events. This study aimed to evaluate the impact of ApoA1 trajectories over three early assessments.
methodsParticipants in the Chin-Shan Community Cardiovascular Cohort with dyslipidemia and receiving three early ApoA1 assessments were enrolled. Group-based multivariate trajectory modeling was used to classify participants into distinct trajectories after multivariable adjustment. The follow-up duration was from April 1990 to August 2022, and the long-term outcomes of major adverse cardiovascular events (MACE) and death outcomes were evaluated.
resultsA total of 1,080 participants were included (median [interquartile range] age 66.14 [57.93-75.04] years, 43.2% males). Participants were classified into four ApoA1 trajectories: Trajectory 1 (low-level persistence pattern); Trajectory 2 (fall-then-rise pattern); Trajectory 3 (rise-then-fall pattern); and Trajectory 4 (elevated stable pattern). The cumulative incidence of MACE was ranked as Trajectory 4 (7.9%) < Trajectory 2 (9.3%) < Trajectory 3 (9.4%) < Trajectory 1 (12.7%). Comparing to Trajectory 4, both Trajectory 1 and Trajectory 2 had significantly higher risks of MACE (Trajectory 1: hazard ratio [HR] = 2.06, 95% confidence interval [CI] 1.10-3.86; Trajectory 2: HR = 2.38, 95% CI 1.03-5.48). For cardiovascular death, similar results were present. There were no significant differences in composite outcome, all-cause death, non-cardiovascular death across ApoA1 trajectories.
conclusionThe trajectory changes of ApoAI levels significantly influences MACE risk during long-term follow-up, particularly in the low-stable and J-shaped trajectories. Dynamic monitoring of ApoAI may serve as a valuable tool for early risk stratification in high-risk populations, facilitating more individualised interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.